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Abstract   
Background: Sorafenib is the current standard treatment for advanced hepatocellular 
carcinoma (HCC). We performed a national audit of UK patients treated with sorafenib 
as standard-of-care and those treated with systemic therapy in first-line trials. 
 
Method: Sorafenib-treated (ST) and trial-treated (TT) patients were identified via the 
Cancer Drugs Fund and local databases. Data were collected retrospectively from 
medical records according to a standard case report form. The primary outcome 
measure was overall survival (OS), estimated by the Kaplan-Meier method.  
 
Results: Data were obtained for 448 ST patients from 15 hospitals. The median age 
was 68 years (range 17-89) and 75% had performance status of ≤1. At baseline, 77% 
were Child-Pugh (CP) A and 16.1% CP B, 38% were ALBI-1 and 48% ALBI-2, 23% 
were BCLC-B and 72% BCLC-C. Median time on sorafenib was 3.6 months with a 
mean daily dose of 590mg. Median OS for 448 evaluable ST patients was 8.5 months. 
There were significant differences in OS comparing; CP A vs CP B, (9.5 vs 4.6 
months), ALBI-1 vs ALBI-2, (12.9 vs 5.9 months) and BCLC-B vs BCLC (13.0 vs 8.3 
months). For TT patients (n=109), the median OS was 8.1 months and this was not 
significantly different from the ST treated patients.  
 
Conclusion: For Child-Pugh A patients with good performance status, survival 
outcomes were similar to those reported in global randomised controlled trials. 
Patients with ALBI grade >1, Child Pugh B or poor performance status appear to derive 
limited benefit from sorafenib treatment.   
Key words; Hepatocellular carcinoma, sorafenib, ALBI, prognosis, Child-Pugh  
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Introduction 
Hepatocellular carcinoma (HCC) is the second most common cause of cancer death 
world-wide and accounted for 746,000 deaths in 2012 [1].  Overall, the prognosis is 
poor and the 5-year age-standardised net survival for adults with liver cancer in the 
UK is 9.3% [2]. To date, sorafenib remains the only drug licenced for the systemic 
treatment of HCC based on the results of two randomised clinical trials which 
demonstrated an improvement in median overall survival of between 2-3 months 
compared with placebo [3, 4]. On this basis, sorafenib was approved for HCC by the 
European Agency for the Evaluation of Medicinal Products (EMA) in 2007 and is 
recommended in international guidelines [5]. 
 
The National Institute for Health and Care Excellence (NICE) and Scottish Medicines 
Consortium (SMC) both published guidance in 2010 and recommended against the 
use of sorafenib for advanced HCC on the basis of cost-effectiveness. However, in 
England, the Cancer Drug Fund (CDF) which was established in April 2011, has 
provided funding for sorafenib as first-line therapy for patients with advanced HCC 
with CP A liver impairment or CP grade B7 liver impairment.  
The clinicopathological characteristics and clinical outcome of patients with advanced 
HCC treated in the UK has not been previously reported and we therefore undertook 
a retrospective national audit to define the patient population treated with sorafenib in 
the UK and the outcome in terms of overall survival 
 
Patients and Methods:  
This was an investigator-initiated collaborative study without industry support. UK 
centres that treat HCC were identified via the UK database of cancer networks, 
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through which cancer care is geographically coordinated in the UK. The Patient Advice 
and Liaison office for each Hospital Trust provided contact details for all clinicians who 
managed patients with HCC, and they were invited to participate in the study. For each 
hospital, HCC patients who had received sorafenib as first-line systemic therapy were 
identified via local Cancer Drugs Fund records or locally held databases. Only patients 
treated within the NHS were included.  In addition, we identified first-line drug trials for 
HCC that were recruiting in UK during the study period.  Anonymised clinical and 
treatment data were collected from medical and pharmacy records according to a 
study-specific case report form. Although toxicity was not recorded according to CTC 
grade, we recorded the adverse events that resulted in dose reduction, interruption or 
termination of treatment and thereby captured toxicity of clinical relevance to patient 
management. The primary outcome measure was overall survival (OS). Ethics 
approval was granted for this research (REC reference 12/LO/1088). 
 
Statistics 
Analyses were performed using Stata version 12.1. OS survival curves were 
generated using Kaplan-Meier methods from commencement of sorafenib to date of 
death or to date of last follow-up. The log-rank test used for comparisons between 
survival curves. Cox proportional hazards regression analysis was used to obtain 
univariate hazard ratios. All variables in Table 1 were considered for inclusion in the 
multivariable model, except where there was co-linearity with existing variables or 
where there was greater than 10% missing data. Continuous variables were analysed 
as categorical variables, with the cut-offs decided as: lower limit of normal range for 
albumin and bilirubin, and AFP; 400 ng/ml. ECOG performance status (PS) was 
included as a categorical variable with three levels (0; 1; 2 or 3). Baseline variables 
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which were associated with overall survival in a univariable Cox model (p<0.1) were 
included in the multivariable model. Kaplan-Meier estimated survival curves were used 
to compare sorafenib and trial-treated patients, and the effect of CP grade, albumin-
bilirubin (ALBI) grade [6] and BCLC stage [7] amongst sorafenib-treated patients. The 
mean daily dose of sorafenib was established by calculating the mean daily dose per 
patient during the course of their treatment and reporting the median mean dose for 
the whole population.  
 
Results:  
Sorafenib treated (ST) patients 
Overall, 17 hospitals were invited to participate and 15 provided data by the agreed 
deadline. In total 448 ST patients were commenced on sorafenib from 1st July 2007 to 
24th July 2013.  Baseline characteristics are shown in Table 1. The majority of patients 
were ECOG PS ≤ 1 (75%), 77% were CP A and 72% BCLC-C. Extra-hepatic disease 
was reported in 38% of which the most common site was lymph node followed by lung 
and then bone. There was a high rate of missing data for vascular invasion but among 
the 252 patients in whom it was recorded, 39% had vascular invasion. the rate of 
vascular involvement was 39% among those in whom it was reported. Of patienThe 
most common single aetiology of background liver disease was alcohol in 25%, and 
42% had previously received prior local therapy for HCC, of whom 74% had 
undergone trans-arterial (chemo) embolisation and 12% had received radiofrequency 
ablation (RFA).   
 
Treatment dose and toxicity 
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Full treatment data were available for 436 patients. The median time on sorafenib 
treatment was 3.6 months with a mean daily sorafenib dose of 590 mg. Overall, 271 
(62%) started at 800mg daily, 143 (33%) started at 400mg daily and the remainder 
started at 200mg (4%) or 600mg (1%) daily. A dose reduction was required in 140 
(52%) patients, and 84 (31%) had their treatment temporarily interrupted due to 
toxicity. The main toxicities leading to a dose reduction or treatment interruption are 
shown in Table 2. Fatigue, deterioration in PS and diarrhoea were the most common 
listed. The frequency of adverse events was similar for CP A and CP B patients with 
the exception of liver dysfunction which was more common in those with CP B disease: 
18% vs 40% for CP A vs B, respectively. The reason sorafenib was discontinued was 
known for 336 patients, of whom 98 (29%) had progressed radiologically, 84 (25%) 
stopped due to toxicity, 63 (19%) had progressed clinically and 65 (19%) died.  
 
Efficacy  
The median OS for 448 evaluable ST patients (342 events) was 8.5 months. In the 
univariate analysis, a significantly decreased risk of death was seen in patients with 
ECOG PS 0, those who had undergone previous local therapy, those with a baseline 
albumin of ≥ 36g/L, bilirubin <17μmol/L, , AFP <400ng/ml and those without vascular 
invasion (Table 3). In the multivariate analysis, the independent predictors of mortality 
were: performance status, previous local therapy, bilirubin, albumin and AFP. Vascular 
invasion was omitted due to high proportion of missing data. The albumin-bilirubin 
(ALBI) grade has recently been described as an alternative to CP as an objective 
measure of liver function that can independently influence survival in patients with 
HCC (6). CP grade, ALBI grade and BCLC stage were included in univariate analysis, 
but omitted from the multivariate analysis due to their co-linearity with albumin, bilirubin 
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or PS. There were significant differences in survival between patients with CP A 
(n=343) vs CP B (n=72); 9.5 vs 4.6 months (Figure 1A). For patients with ALBI-1 
(n=168) vs ALBI-2 (n=214), the median survival was 12.9 vs 5.9 months (Figure 1B). 
For BCLC B (n=104) vs C (n=322), the median survival was 13.0 vs 8.3 months (Figure 
1C).  
 
Trial treated (TT) patients 
Data were collected on 109 TT patients who were recruited to five first line trials for 
advanced HCC in five of the contributing hospitals. Details of the study and recruitment 
are given in Table 4.  The baseline characteristics are listed in Table 1 and, compared 
to the ST cohort; the TT cohort tended to have a higher proportion of ECOG PS 0 and 
CP A patients, but also had a greater proportion with vascular involvement and extra-
hepatic disease.  The median time on trial drug was 3.7 months. Median OS was 8.1 
months for 109 TT patients (91 events). There was no difference in survival between 
ST vs TT patients: unadjusted HR = 0.95 (95%CI 0.71-1.20), p=0.69 (Figure 1D).  
 
Discussion:  
Further to the data obtained from randomised clinical trials, observational studies 
provide important additional information on the efficacy and toxicity of therapy when 
applied to a larger and more diverse population which is distinct from the highly 
selected trial population [8].  Moreover, for the treatment of hepatocellular carcinoma, 
where geographical and aetiological differences result in profound differences in 
outcome [9], it is important to understand the relevance of a global trial such as the 
SHARP trial to the local population. The UK data presented here show that median 
OS survival of ST patients in the UK was equivalent to that reported in clinical trials 
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when the key selection criteria are considered. An exploratory multivariate analysis 
within the SHARP trial identified, among other factors, ECOG PS and CP status as 
having a significant impact on survival [3]. In SHARP, 54% were PS 0 and 95% CP A 
compared with 26% and 77% respectively in our study. In a sub-analysis of SHARP, 
those with a PS of 0 had an OS of 13.3 months compared to 8.9 months for those with 
PS 1-2 illustrating the relevance of PS to OS [10]. In subsequent global, randomised 
trials in which sorafenib has been used as the control arm, the reported OS for 
sorafenib treated patients has ranged from 8.5 to 10.2  months [11-14]. Recruitment 
to many of these trials was ongoing in the UK and approximately 20% of UK patients 
receiving systemic therapy went into first-line trials. We therefore included these 
patients in a parallel analysis to explore the possibility that the exclusion of these 
patients from routine care biased the study. Surprisingly, we found no difference in 
median OS between the trial and non-trial treated cohorts. However, the imbalance 
between the treatments received and some baseline characteristics prevents further 
interpretation of this observation.  
 
There are few large, multicentre observational studies with which to compare our data. 
An Italian collaborative study group (SOFIA) has published a field-practice study 
including prospective data from 296 patients from six centres and reported a median 
OS of 10.5 months; 8.5 months in BCLC-C and 20.6 months in BCLC-B [15]. In this 
study 56% had PS0 and 88% were CP A so were more comparable with the SHARP 
population. Additionally, 51% had hepatitis C only as a cause of chronic liver disease 
compared with 16% in our population and hepatitis C has been proposed as a positive 
predictive factor for survival with sorafenib [10]. In common with both SHARP and the 
SOFIA study, we show that bilirubin and albumin are significant independent 
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predictors of survival for patients treated with sorafenib. Another multicentre 
retrospective study from Austria has also been reported including 148 patients from 
11 institutions [16]. Median OS was 7.4 months but only 52% were CP A, and CP 
score was a significant prognostic factor in multivariate analysis. This raises the 
question to what extent those with impaired liver function benefit from sorafenib. Since 
all large randomised trials including sorafenib for HCC have excluded CP B patients, 
information regarding toxicity and efficacy is predominantly available from other 
sources. The GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular 
carcinoma and Of its treatment with sorafeNib) study is an industry sponsored global 
non-interventional study designed primarily to assess safety of sorafenib in the real 
life population [17]. The first interim analysis included 479 patients of which 143 were 
European and demonstrated that overall, 28% of those treated had CP B disease. 
While they reported similar toxicity comparing patients with CP A and B, they did not 
provide a breakdown by specific toxicity and it was noted that sorafenib was 
discontinued due to toxicity in 40% CP B patients compared with 25% CP A patients.  
Here, we show that deterioration in PS and liver function was more frequent in CP B 
patients, in keeping with data reported from a small German study [18]. Moreover, 
compared with CP A, the survival in patients with CP B disease was significantly worse 
at 4.6 months.  The inferior survival of CP B patients treated with sorafenib has been 
shown in other studies and ranges from 2.0-7.7months and the appropriate 
stratification of patients according to liver function is therefore of key importance [15, 
18-22]. Recently, the ALBI grade has been developed and proposed as an alternative 
to CP method to assess liver function in patients with HCC [6]. The ALBI grade is 
based only on albumin and bilirubin measured as continuous variables, and avoids the 
inherent subjectivity of some elements of CP score. As part of its validation, the ALBI 
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grade was evaluated in 1,132 patients receiving sorafenib on clinical trials of which 
96% were CP A. Our analysis presented an opportunity to evaluate the ALBI grade in 
sorafenib-treated patients outside clinical trials and compare with broader range of CP 
grade. Interestingly we found that survival of patients with ALBI grade 1 was very 
similar when comparing our cohort (12.9 months) with the ALBI 1 trial cohort (12.7 
months). For the ALBI 2 grade, the survival for our cohort was worse at 5.9 months 
compared with 7.2 months in the trial cohort which presumably reflects the inclusion 
of more CP B patients in our ALBI 2 cohort. The ALBI score may therefore provide a 
useful method of stratification in trials which are predominantly CP A and help with 
prognostication in the clinic. However CP seems to provide information to help select 
those with a particularly poor outlook that may not benefit from sorafenib.  
 
The main limitations of our study were that it was retrospective. To minimise the impact 
of this, we chose a robust OS primary endpoint and sufficient follow-up such that the 
endpoint had been met in 76% cases at the time of analysis. Moreover, for most of the 
key prognostic variables data were available in around 90% cases. The exception was 
vascular invasion for which there was a high rate of missing data. However the 
reported rate of 39% is consistent with the SHARP trial in which vascular involvement 
was reported in 36% and 41% in the sorafenib and placebo arms respectively. 
Although toxicity was not recorded according to CTC criteria, we were able capture 
clinically relevant toxicity that resulted in dose reductions, interruption or termination 
of therapy. We did not collect data on post-sorafenib therapy but this would have been 
supportive care or second-line trials. Since all second-line trials conducted during this 
period were negative, we do not believe that post-sorafenib therapy influenced 
outcome.  Finally, in the absence of an untreated control group, it is difficult to evaluate 
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the absolute benefit of sorafenib in the UK population. However previously published 
data from UK patients deemed suitable for sorafenib but for whom funding was denied 
suggests a median OS of 4.1 months [23]. 
 
In summary our large collaborative study provides the first comprehensive survey of 
sorafenib use for HCC in the UK. We have defined the patient population in which it 
has been used, the outcome in terms of survival and associated prognostic variables. 
We have shown that the survival of the CP A population is in keeping with results 
reported in recent global randomized clinical trials and equivalent to that of patients 
treated in first-line UK trials. However, patients with Child-Pugh B liver function and 
poor performance status appear to derive limited benefit from sorafenib treatment and 
may be better managed with supportive care.  
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Table 1: baseline demographic and clinical characteristics of HCC patients who 
received sorafenib as first line systemic therapy or were treated first line on clinical 
trials  
 Observational (N=448) Trial (N=109) 
Age at entry; median (range) 68 (17.0 - 89.0) 68 (26.0 - 85.0) 
Sex   
Male 325 (72.5%) 87 (79.8%) 
Female 66 (14.7%) 13 (11.9%) 
No data 57 (12.7%) 9 (8.3%) 
Extra-hepatic disease   
No 269 (60.0%) 42 (38.5%) 
Yes 172 (38.4%) 61 (56.0%) 
    Lymph node 66  (14.7%) 32  (29.4%) 
    Lung 59  (13.2%) 19  (17.4%) 
    Bone 29  (6.5%) 12  (11.0%) 
No data 7 (1.6%) 6 (5.5%) 
ECOG PS   
0 117 (26.1%) 48 (44.0%) 
1 218 (48.7%) 58 (53.2%) 
2 94 (21.0%) 3 (2.8%) 
3 6 (1.3%) - 
No data 13 (2.9%) - 
Previous local therapy   
No 258 (57.6%) 52 (47.7%) 
Yes 190 (42.4%) 57 (52.3%) 
Vascular invasion   
No 161 (35.9%) 58 (53.2%) 
Yes 91 (20.3%) 36 (33.0%) 
No data 196 (43.8%) 15 (13.8%) 
Bilirubin (µmol/L)   
< 17 238 (53.1%) 68 (62.4%) 
≥ 17  158 (35.3%) 36 (33.0%) 
No data 52 (11.6%) 5 (4.6%) 
13 
 
Albumin (g/L)   
< 36 121 (27.0%) 29 (26.6%) 
≥ 36  276 (61.6%) 75 (68.8%) 
No data 51 (11.4%) 5 (4.6%) 
Hepatitis B   
No 393 (87.7%) 96 (88.1%) 
Yes 55 (12.3%) 13 (11.9%) 
Hepatitis C   
No 378 (84.4%) 97 (89.0%) 
Yes 70 (15.6%) 12 (11.0%) 
Alcohol   
No 338 (75.4%) 92 (84.4%) 
Yes 110 (24.6%) 17 (15.6%) 
Child Pugh    
A 343 (76.6%) 100 (91.7%) 
B 72 (16.1%) 7 (6.4%) 
C 2 (0.4%) - 
No data 31 (6.9%) 2 (1.8%) 
ALBI grade   
1 168 (37.5%) 47 (43.1%) 
2 214 (47.8%) 57 (52.3%) 
3 14 (3.1%) 1 (0.9%) 
No data 52 (11.6%) 4 (3.7%) 
AFP (ng/ml)   
<400 227 (50.7%) 51 (46.8%) 
≥400 141 (31.5%) 51 (46.8%) 
No data 80 (17.9%) 7 (6.4%) 
BCLC   
A 3 (0.7%) 1 (0.9%) 
B 104 (23.2%) 11 (10.1%) 
C 322 (71.9%) 95 (87.2%) 
No data 19 (4.2%) 2 (1.8%) 
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Abbreviations - ST: sorafenib treated; TT: trial treated; ECOG PS: Eastern Cooperative Group 
Performance Status; ALBI: albumin-bilirubin score; AFP: alphafetoprotein; BCLC: Barcelona 
Clinic Liver Cancer stage classification  
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Table 2: Adverse events leading to a dose reduction or treatment interruption for ST 
patients   
 
Overall % 
n=224 
CP A % 
n=181 
CP B % 
n=43 
Fatigue 45 45 47 
PS deterioration 33 32 47 
Diarrhoea 32 33 30 
Skin toxicity 24 23 33 
Liver Function 22 18 40 
Nausea 12 12 16 
Weight Loss 9 10 5 
Gastrointestinal bleed 7 7 5 
Myelosuppression  5 6 2 
Other 17 17 21 
 
CP: Child Pugh; PS: drop in performance status; Liver Function (bilirubin or transaminases) 
  
16 
 
Table 3: Risk factors for overall mortality in HCC patients treated with sorafenib 
 
Variable 
Univariable Multivariable* 
HR (95% CI) p-value HR (95% CI) p-value 
ECOG PS 
0 - 
0.008 
- 
0.055 1 1.45 (1.11 - 1.88) 1.41 (1.05 - 1.89) 
2 or 3 1.54 (1.13 - 2.11) 1.39 (0.98 - 1.97) 
Previous local 
therapy 
No - 
0.004 
- 
0.023 
Yes 0.73 (0.58 - 0.90) 0.74 (0.58 - 0.96) 
Bilirubin 
µmol/L 
< 17 - 
< 0.001 
- 
<0.001 
≥ 17  1.56 (1.24 - 1.97) 1.68 (1.30 - 2.16) 
Albumin 
g/L 
< 36 - 
< 0.001 
- 
0.025 
≥ 36  0.60 (0.47 - 0.76) 0.74 (0.56 - 0.96) 
AFP 
ng/ml 
<400 - 
0.001 
- 
0.008 
≥400 1.51 (1.19 - 1.93) 1.41 (1.09 - 1.82) 
Sex 
Male - 
0.726 
  
Female 1.06 (0.78 - 1.44)   
Extra-hepatic 
disease 
No - 
0.521 
  
Yes 1.07 (0.86 - 1.34)   
Vascular 
invasion 
No - 
0.013 
  
Yes 1.44 (1.08 - 1.91)   
Hepatitis B 
No - 
0.792 
  
Yes 0.96 (0.69 - 1.33)   
Hepatitis C 
No - 
0.070 
  
Yes 1.30 (0.98 - 1.73)   
Alcohol 
No - 
0.477 
  
Yes 1.10 (0.85 - 1.41)   
Child Pugh  
A - 
0.003 
  
B 1.53 (1.16 – 2.03)   
ALBI grade 
1 - 
<0.001 
  
2 1.92 (1.51 – 2.44)   
BCLC 
2 - 
0.006 
  
3 1.45 (1.11 – 1.89)   
17 
 
Abbreviations: ECOG PS – Eastern Cooperative Group Performance Status; AFP: alpha 
fetoprotein;  ALBI: albumin-bilirubin score; BCLC: Barcelona Clinic Liver Classification 
*Vascular invasion omitted from multivariable model due to missing data. Child Pugh, ALBI 
and BCLC omitted from multivariable model due to co-linearity with albumin, bilirubin or 
performance status. 
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Table 4: First-line systemic therapy trials for HCC in which the TT patients were 
enrolled. 
Trial name 
 
Description 
SEARCH [14] 
N=41 
Phase III  
sorafenib+ erlotinib vs sorafeninb +placebo 
Nintedanib 
N=35 
Phase I  Nintedanib  
Phase II Nintedanib vs Sorafenib 
BRISK FL [13] 
N=26 
Phase III  
sorafenib vs brivanib 
SHARP[3] 
N=6 
Phase III RCT 
Sorafenib vs placebo  
E7050 
N=3 
Randomised Phase Ib/II 
sorafenib +E7050 vs sorafenib  
 
 
 
Figure Legend 
Figure 1. Kaplan Meier survival curves of OS comparing A) Child-Pugh A vs Child-
Pugh B, B) ALBI 1 vs ALBI 2, C) BCLC B vs BCLC C, D) Sorafenib treated 
(observational) vs Trial treated (trial) 
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